References
- Ali M, Al-Hendy A. Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids. Biol Reprod. 2017 Sep 1;97(3):337–352. PubMed PMID: 29025038.
- Brito LG, Panobianco MS, Sabino-de-Freitas MM, et al. Uterine leiomyoma: understanding the impact of symptoms on womens’ lives. Reprod Health. 2014 Jan 30;11(1):10. PubMed PMID: 24476380; PubMed Central PMCID: PMCPMC3909443.
- Ali M, Chaudhry ZT, Al-Hendy A. Successes and failures of uterine leiomyoma drug discovery. Expert Opin Drug Discov. 2018 Feb;13(2):169–177. PubMed PMID: 29254389.
- LA. LUPRON DEPOT® 3.75 mg - Food and Drug administration (FDA) drugs. 2011. [cited 2018 May]. Available from: https://wwwaccessdatafdagov/drugsatfda_docs/label/2011/019943s032,020011s039lblpdf.
- Moroni RM, Martins WP, Ferriani RA, et al. Add-back therapy with GnRH analogues for uterine fibroids. Cochrane Database Syst Rev. 2015 Mar 20;(3):CD010854. PubMed PMID: 25793972. DOI:10.1002/14651858.CD010854.pub2.
- Melis GB, Neri M, Corda V, et al. Overview of elagolix for the treatment of endometriosis. Expert Opin Drug Metab Toxicol. 2016 May;12(5):581–588. PubMed PMID: 27021205.
- Donnez J, Arriagada P, Donnez O, et al. Emerging treatment options for uterine fibroids. Expert Opin Emerg Drugs. 2018 Mar;23(1):17–23. PubMed PMID: 29486606.
- Ferrero S, Vellone VG, Barra F. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids. Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):107–116. PubMed PMID: 29250979.
- Pohl O, Zobrist RH, Gotteland JP. The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids. Reprod Sci. 2015 Apr;22(4):476–483. PubMed PMID: 25228633; PubMed Central PMCID: PMCPMC4812693.
- Nieman LK, Blocker W, Nansel T, et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril. 2011 Feb;95(2):767–72 e1-2. PubMed PMID: 21055739; PubMed Central PMCID: PMCPMC4180231.
- EMA. EMA starts review of Esmya for uterine fibroids; Review triggered by cases of liver injury. 2018. [cited 2018 May]. Available from: http://wwwemaeuropaeu/docs/en_GB/document_library/Referrals_document/Esmya_20/Procedure_started/WC500239713pdf
- Melis GB, Neri M, Piras B, et al. Vilaprisan for treating uterine fibroids. Expert Opin Investig Drugs. 2018 May;27(5):497–505. PubMed PMID: 29718788.
- Schultze-Mosgau MH, Schuett B, Hafner FT, et al. Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women. Int J Clin Pharmacol Ther. 2017 Jan;55(1):16–24. PubMed PMID: 27841155.
- EMA. Women taking Esmya for uterine fibroids to have regular liver tests while EMA review is ongoing. 2018. cited 2018 May. Available from: http://wwwemaeuropaeu/docs/en_GB/document_library/Press_release/2018/02/WC500243548pdf.
- Liu R, Yu X, Wallqvist A. Data-driven identification of structural alerts for mitigating the risk of drug-induced human liver injuries. J Cheminform. 2015;7:4. PubMed PMID: 25717346; PubMed Central PMCID: PMCPMC4339691.